Inflammation in the genesis of hypertension and its complications - The role of angiotensin II

Nephrology Dialysis Transplantation

Volumn 22, Issue 11, 2007, Pages 3107-3109

  Li, Jun ^a   Doerffel, Yvonne ^a   Hocher, Berthold ^a   Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin II; Hypertension; Inflammation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HUMORAL ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; BLOOD LEVEL; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; HUMAN; HYPERTENSION; INFLAMMATION; INHIBITION KINETICS; MECHANICAL STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CYTOKINES; HUMANS; HYPERTENSION; INFLAMMATION;

EID: 36749102649     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm469     Document Type: Editorial

References (28)

1. Shamsuzzaman ASM, Winnicki M, Lanfranchi P et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-2464
2. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 2000; 14: 83-90
3. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006
4. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-Reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951
5. Biasucci LM, Liuzzo G, Fantuzzi G et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-2084
6. Ballantyne CM, Entman ML. Soluble adhesion molecules and the search for biomarkers for atherosclerosis. Circulation 2002; 106: 766-767
7. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-{kappa}B transcription factors. Circ Res 1999; 84: 695-703
8. Ruiz-Ortega M, Ruperez M, Lorenzo O et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney International 2002; 62: S12-S22
9. Doerffel Y, Latsch C, Stuhlmuller B et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-117
10. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46: 1118-1122
11. Pfab T, Chen YP, Slowinski T et al. Impact of genes related to immune tolerance and inflammation (tumour necrosis factor-alpha, interleukin-6) on blood pressure, protein excretion and oedema in pregnancy. J Hypertens 2005; 23: 2187-2191
12. Pfab T, Stirnberg B, Sohn A et al. Impact of maternal angiotensinogen M235T polymorphism and angiotensin-converting-enzyme insertion/deletion polymorphism on blood pressure, protein excretion and fetal outcome in pregnancy. J Hypertens 2007; 25: 1255-1261
13. Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn AO. Localization of angiotensin converting enzyme in rat heart. Circ Res 1991; 68: 141-149
14. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998; 98: 800-807
15. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923
16. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148
17. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472
18. Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different? Am J Cardiol 1999; 84: 9S-15S
19. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998; 188: 661-670
20. Li J, Culman J, Hortnagl H et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. Faseb J 2005; 19: 617-619, Epub 2005 Jan 21
21. Wu L, Iwai M, Nakagami H et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with Valsartan in the improvement of inflammation-induced vascular Injury. Circulation 2001; 104: 2716-2721
22. The Heart Outcomes Prevention Evaluation Study Investigators.Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153
23. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet 2002; 359: 995-1003
24. Schieffer B, Wirger A, Meybrunn M et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994; 89: 2273-2282
25. Sironi L, Gelosa P, Guerrini U et al. Anti-Inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2004; 311: 989-995
26. Schieffer B, Bunte C, Witte J et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am College Cardiol 2004; 44: 362-368
27. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-{gamma} activity. Circulation 2004; 109: 2054-2057
28. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007; 115: 518-533